

Antifungals, Oral Review

01/14/2010

Copyright © 2004 – 2010 by Provider Synergies, L.L.C. All rights reserved.
Printed in the United States of America.

All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage and retrieval system without the express written consent of Provider Synergies, L.L.C.

All requests for permission should be mailed to:

*Attention: Copyright Administrator
Intellectual Property Department
Provider Synergies, L.L.C.
10101 Alliance Rd, Ste 201
Cincinnati, Ohio 45242*

The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to PSTCEditor@magellanhealth.com.



Together, we can do more.

Antifungals, Oral Review

FDA-Approved Indications

Drug	Manufacturer	FDA-Approved Indication(s) for oral use
clotrimazole (Mycelex Troche®) ¹	generic	<ul style="list-style-type: none"> Treatment of oropharyngeal candidiasis To reduce the incidence of oropharyngeal candidiasis in patients immunocompromised by conditions that include chemotherapy, radiotherapy, or steroid therapy utilized in the treatment of leukemia, solid tumors, or renal transplantation
fluconazole (Diflucan®) ²	generic	<ul style="list-style-type: none"> Treatment of oropharyngeal, esophageal, and vaginal candidiasis Treatment of urinary tract infections, peritonitis, systemic infections including candidemia, disseminated candidiasis, and pneumonia Cryptococcal meningitis in AIDS patients Prevention of candidiasis in patients undergoing bone marrow transplantation with cytotoxic chemotherapy and/or radiation
flucytosine (Ancobon®) ³	Valeant	<ul style="list-style-type: none"> Serious infections caused by susceptible strains of <i>Candida</i> or <i>Cryptococcus</i> in combination with amphotericin B
griseofulvin suspension ⁴	generic	<ul style="list-style-type: none"> Ringworm infections of the body, skin, hair, and nails, namely tinea corporis, tinea pedis, tinea cruris, tinea barbae, tinea capitis, and tinea unguium (onychomycosis)
griseofulvin (Grifulvin® V) ⁵	OMJPI	
griseofulvin (Gris-PEG®) ⁶	Pedinol	
itraconazole (Sporanox®) ⁷	generic	<ul style="list-style-type: none"> Blastomycosis, histoplasmosis, and aspergillosis in non-immunocompromised and immunocompromised patients Onychomycosis of the fingernail and/or toenail due to dermatophytes (tinea unguium) in non-immunocompromised patients
ketoconazole (Nizoral®) ⁸	generic	<ul style="list-style-type: none"> Candidiasis, chronic mucocutaneous candidiasis, oral thrush, candiduria, blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, paracoccidioidomycosis, and severe recalcitrant cutaneous dermatophyte infections not responding to topical therapy or oral griseofulvin
nystatin (Mycostatin®) ⁹	generic	<ul style="list-style-type: none"> Intestinal and oral candidiasis
posaconazole (Noxafil®) ¹⁰	Schering	<ul style="list-style-type: none"> Prophylaxis of invasive <i>Aspergillus</i> and <i>Candida</i> infections in patients 13 years and older who are at high risk of developing these infections due to being severely immunocompromised (e.g. hematopoietic stem cell transplant recipient with graft versus host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy) Treatment of oropharyngeal candidiasis, including oropharyngeal candidiasis refractory to itraconazole and/or fluconazole
terbinafine (Lamisil®) ¹¹	generic	<ul style="list-style-type: none"> Onychomycosis of the toenail or fingernail due to dermatophytes (tinea unguium)
terbinafine (Lamisil® Granules) ¹²	Novartis	<ul style="list-style-type: none"> Treatment of tinea capitis in patients four years of age and older
terbinafine (Terbinex™) ¹³	JSJ Pharmaceuticals	<ul style="list-style-type: none"> Treatment of onychomycosis of the toenail or fingernail due to dermatophytes (tinea unguium)
voriconazole (Vfend®) ¹⁴	Pfizer	<ul style="list-style-type: none"> Treatment of invasive aspergillosis Serious fungal infections caused by <i>Scedosporium apiospermum</i> and <i>Fusarium solani</i> Treatment of esophageal candidiasis Treatment of candidemia in non-neutropenic patients and disseminated infections in skin and infections in abdomen, kidney, bladder wall, and wounds

Overview

The antifungal agents have different spectrums of activity and are FDA-approved to treat a variety of infections. Few trials have been performed to compare safety and efficacy profiles of the drugs. In addition, many of the agents carry black box warnings related to adverse events and/or drug interactions.

The Infectious Diseases Society of America (IDSA) 2009 guidelines on the treatment of oropharyngeal candidiasis in adults include clotrimazole troches (Mycelex) or nystatin for mild disease; for moderate to severe disease, fluconazole (Diflucan) is recommended.¹⁵ For fluconazole-refractory disease, itraconazole solution or posaconazole suspension (Noxafil) may be used. In other refractory cases, voriconazole (Vfend) or amphotericin B oral suspension may be administered. Chronic suppressive therapy for patients with human immunodeficiency virus (HIV) is not always necessary. If suppressive therapy is required, fluconazole is recommended.

Since highly active antiretroviral therapy (HAART) for the treatment of HIV for infants and children is widely available and utilized in the US, routine primary prophylaxis of candidiasis is not indicated.¹⁶ Uncomplicated infections can be effectively treated with topical therapy such as clotrimazole troches or nystatin. Troches should not be used in infants. Systemic therapy with fluconazole, ketoconazole, or itraconazole may be considered for the initial treatment of oropharyngeal candidiasis. Fluconazole is more effective than nystatin for infants. Itraconazole has equivalent efficacy to fluconazole for oropharyngeal candidiasis, but it is less well tolerated. Ketoconazole absorption can be variable so it is recommended to use fluconazole or itraconazole solutions when available.

The IDSA 2009 guidelines also recommend oral fluconazole for patients with symptomatic cystitis secondary to *Candida*. Oral fluconazole or topical antifungals are recommended for vulvovaginal candidiasis.

For esophageal candidiasis in adults, fluconazole, oral or IV, is considered first line.¹⁷ Fluconazole or itraconazole are preferred for children for the management of esophageal candidiasis.¹⁸ Posaconazole, itraconazole, or voriconazole may be used in patients with fluconazole-refractory infections.

Onychomycosis is a nail disease that is often chronic, difficult to eradicate, and has a tendency to recur. Onychomycosis is found more frequently in the elderly. The most common clinical presentations are distal and lateral subungual onychomycosis (which usually affects the great or first toe) and white superficial onychomycosis (which generally involves the third or fourth toes). Oral antifungal therapy with terbinafine (Lamisil) or itraconazole (Sporanox) has improved cure rates; however, up to 25 percent of patients have persistent disease.¹⁹

Opportunistic fungal infections are particularly likely to occur in patients during corticosteroid, immunosuppressant, or antimetabolite therapy, or in patients with Acquired Immunodeficiency Syndrome (AIDS), azotemia, diabetes mellitus, bronchiectasis, emphysema, tuberculosis, lymphoma, leukemia, or burns. Histoplasmosis, coccidioidomycosis, cryptococcosis, blastomycosis, paracoccidioidomycosis, and sporotrichosis are systemic mycoses which can cause disease in both healthy and immunocompromised individuals. In contrast, mycoses caused by opportunistic fungi such as *Candida albicans*, *Aspergillus spp*, *Trichosporon*, *Torulopsis (Candida) glabrata*, *Fusarium*, *Alternaria*, and *Mucor* are generally found only in an immunocompromised host.

Pharmacology

Drug	Mechanism of Action
clotrimazole (Mycelex Troche) ²⁰	Inhibits the action of fungal ergosterol synthesis; interacts with the cytochrome P450 enzyme 14-alpha demethylase; inhibits growth of pathogenic yeasts by altering cell membrane permeability
fluconazole (Diflucan) ²¹	Highly selective inhibitor of fungal cytochrome P450 sterol C-14 alpha-demethylation, which results in fungistatic activity
flucytosine (Ancobon) ²²	Enters the fungal cell and is metabolized to 5-fluorouracil, which is extensively incorporated into fungal RNA and inhibits synthesis of both DNA and RNA; the result is unbalanced growth and death of the fungal organism
griseofulvin ²³	Fungistatic amounts are deposited in the keratin, which is gradually exfoliated and replaced by non-infected tissue
itraconazole (Sporanox) ²⁴	Inhibits the cytochrome P450-dependent synthesis of ergosterol, a vital component of fungal cell membranes
ketoconazole (Nizoral) ²⁵	Impairs the synthesis of ergosterol, a vital component of fungal cell membranes
nystatin (Mycostatin) ²⁶	Binds to sterols in the fungal cell membranes which leads to fungistatic activity
posaconazole (Noxafil) ²⁷	Inhibits cytochrome P450-dependent 14- α demethylase in the biosynthetic pathway of ergosterol
terbinafine (Lamisil, Lamisil Granules, Terbinex) ^{28,29,30}	Inhibits squalene epoxidase, a key enzyme in fungal sterol biosynthesis; fungicidal <i>in vitro</i> depending on organism and concentration
voriconazole (Vfend) ³¹	Inhibits ergosterol synthesis by interacting with the 14-alpha-lanosterol demethylation step, a cytochrome P450 enzyme

In the Terbinex kit, topical hydroxypropyl chitosan or HPCH (Eco Formula) is a companion topical product designed to enhance nail growth and improve the appearance of dystrophic nails.

Pharmacokinetics

Drug	Bioavailability (%)	Half-life (hr)	Metabolism	Excretion (%)	CYP 450 Enzyme Inhibition
clotrimazole (Mycelex Troche) ³²	negligible absorption	--	--	--	--
fluconazole (Diflucan) ³³	>90	20-50	--	Renal: 91	2C9, 3A4
flucytosine (Ancobon) ³⁴	78-89	2.4-4.8	Small amount of flucytosine is deaminated (probably by gut bacteria) to 5-fluorouracil and reabsorbed	Renal: 90 Fecal: <10	--
griseofulvin ³⁵	varies with formulation	9-24	No active metabolites	Both renal and fecal excretion	--
itraconazole (Sporanox) ³⁶	55	64	Several metabolites; hydroxyitraconazole is the major active metabolite	Renal: 40 Fecal: 3-18	3A4
ketoconazole (Nizoral) ³⁷	-- (requires acidic pH)	8	Several inactive metabolites	Renal: 13 Bile: 87	3A4
nystatin (Mycostatin) ³⁸	poorly absorbed	--	--	Predominantly feces	--
posaconazole (Noxafil) ³⁹	-- (varies based on fed or fasting state)	20-66	No active metabolites	Renal: 13 Fecal: 71	3A4
terbinafine (Lamisil, Terbinex) ^{40,41}	40	200-400	No active metabolites	Renal: 70	2D6
terbinafine (Lamisil Granules) ⁴²	--	9.3-13.8	No active metabolites	Renal: 70	2D6
voriconazole (Vfend) ⁴³	96	dose dependent	N-oxide metabolite is inactive; several other inactive metabolites	Renal: 80-83	2C19, 2C9,3A4

Contraindications/Warningsclotrimazole (Mycelex)

Clotrimazole is not indicated for systemic mycoses including systemic candidiasis.⁴⁴

fluconazole (Diflucan)⁴⁵

Fluconazole is contraindicated in patients with hypersensitivity to fluconazole or any of its excipients. There is no information regarding cross-hypersensitivity among fluconazole and other azole antifungal agents. Caution should be used in prescribing fluconazole to patients with hypersensitivity to other azoles.

Fluconazole is contraindicated with concurrent administration of terfenadine and cisapride; both agents are no longer available in the US.

Fluconazole has been associated with rare reports of anaphylaxis, serious hepatic toxicity, and exfoliative skin disorders during treatment.

Fluconazole has been associated with rare cases of serious hepatic toxicity, including fatalities, primarily in patients with serious underlying medical conditions. There has been no obvious relationship to total daily dose, duration of therapy, sex, or age of the patients in the known cases of fluconazole-associated hepatotoxicity. Fluconazole hepatotoxicity has usually, but not always, been reversible upon discontinuation. Patients with abnormal liver function tests during fluconazole therapy should be monitored for more severe hepatic injury. Discontinue fluconazole therapy if clinical signs and symptoms of liver disease develop during therapy.

flucytosine (Ancobon)

There is a black box warning associated with flucytosine which stresses monitoring of renal, hepatic, and hematologic status.⁴⁶ Use with extreme caution in patients with renal impairment or bone marrow depression.

griseofulvin (Grifulvin V, Gris-PEG)

Griseofulvin is contraindicated in the first trimester of pregnancy. Additionally, griseofulvin is contraindicated in patients with porphyria or hepatocellular failure.⁴⁷

itraconazole (Sporanox)⁴⁸

Itraconazole is contraindicated in patients with ventricular dysfunction as evidenced by congestive heart failure (CHF) or a history of CHF. Itraconazole should not be administered to women considering pregnancy or who are pregnant. Itraconazole should not be administered with cisapride, lovastatin, oral midazolam, nisoldipine (Sular[®]), pimozide, quinidine, dofetilide, simvastatin, triazolam, or levacetylmethadol (levomethadyl) as this may result in elevated plasma concentration of those drugs leading to potentially serious adverse events. Itraconazole should not be administered with the ergot alkaloids such as dihydroergotamine, ergometrine (ergonovine), ergotamine, and methylergometrine (methylergonovine).

A black box warning associated with itraconazole stresses that itraconazole should not be used for onychomycosis in patients with evidence of ventricular dysfunction or congestive heart failure due to the risk of pulmonary edema and/or congestive heart failure (CHF). Negative inotropic effects have been observed with intravenous itraconazole. Serious cardiovascular events, including QTc prolongation, torsades de pointes, ventricular tachycardia, cardiac arrest, and/or sudden death have occurred when itraconazole is coadministered with inhibitors of CYP450 3A4 isoenzyme.

Calcium channel blockers can have negative inotropic effects which may be additive to those of itraconazole. In addition, itraconazole can inhibit the metabolism of calcium channel blockers.

Therefore, caution should be used when coadministering itraconazole and calcium channel blockers due to an increased risk of CHF.

Transient or permanent hearing loss has been reported in patients receiving treatment with itraconazole. Several of these reports included concurrent administration of quinidine which is contraindicated. The hearing loss usually resolves when treatment is stopped but can persist in some patients.

Itraconazole capsules and oral solution should not be used interchangeably as the drug exposure is greater with the oral solution than with the capsules when the same dose is administered. Only the oral solution or itraconazole has demonstrated efficacy for oral and/or esophageal candidiasis.

Serious hepatotoxicity, including liver failure and death, has been associated with itraconazole. Some patients did not have an underlying medical condition or pre-existing liver disease. Hepatotoxicity may develop as early as the first week of therapy with itraconazole. If signs or symptoms develop that are consistent with liver disease, itraconazole therapy should be discontinued, and liver function tests performed.

Both itraconazole and terbinafine prescribing information recommend, "Prior to initiating treatment, appropriate nail specimens for laboratory testing (KOH preparation, fungal culture, or nail biopsy) should be obtained to confirm the diagnosis of onychomycosis." A warning for both terbinafine and itraconazole states that neither agent should be used in patients with pre-existing liver disease, and rare cases of liver failure have occurred during use of either product.

ketoconazole (Nizoral)^{49,50}

Ketoconazole should not be administered with terfenadine, astemizole, cisapride, or triazolam.

A black box warning states that ketoconazole has been linked to hepatic toxicities and fatalities. Monitoring of hepatic function is recommended.

posaconazole (Noxafil)⁵¹

Posaconazole is contraindicated in coadministration with sirolimus and ergot alkaloids. Posaconazole is also contraindicated in coadministration with the CYP3A4 substrates, terfenadine, astemizole, cisapride, pimozone, halofantrine, or quinidine, since this may result in increased plasma concentrations of these agents leading to QTc prolongation and rare occurrences of torsades de pointes.

Infrequent cases of hepatic reactions such as mild to moderate elevations in alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, total bilirubin, and/or clinical hepatitis have been reported with posaconazole. Liver enzyme elevations were generally reversible upon discontinuation or in some cases, normalized without drug interruption, and rarely required drug discontinuation. More serious hepatic reactions including cholestasis or hepatic failure including fatalities have been reported in patients with serious underlying medical conditions such as hematologic malignancy during treatment with posaconazole. Posaconazole 800 mg daily has been associated with the more severe hepatic reactions. Liver function tests should be evaluated at therapy initiation and during the course of posaconazole therapy. If abnormal liver function tests occur during posaconazole therapy, monitor for the development of more severe hepatic injury. Posaconazole should be discontinued if worsening of liver function tests continues.

Elevated cyclosporine levels resulting in rare serious adverse events including nephrotoxicity, leukoencephalopathy and death were reported in clinical efficacy trials for posaconazole. Dose reduction and more frequent monitoring of cyclosporine and tacrolimus should be performed when posaconazole therapy is initiated.

Posaconazole is contraindicated in patients with hypersensitivity to it or its excipients. There is no information regarding cross-sensitivity among posaconazole and other azole antifungal agents. Caution should be used when prescribing posaconazole to patients with hypersensitivity to other azoles.

Posaconazole should be administered with caution to patients with potentially proarrhythmic conditions and should not be administered with drugs that are known to prolong the QTc interval and are metabolized through CYP3A4. Rigorous attempts to correct potassium, magnesium, and calcium should be made before starting posaconazole.

terbinafine (Lamisil, Lamisil Granules, Terbinex)^{52,53,54}

Terbinafine is contraindicated in patients with a history of allergic reaction to oral terbinafine because of the risk of anaphylaxis. Severe hepatic injury, including liver failure, with some leading to death or liver transplantation has occurred with the use of oral terbinafine. Assessment of serum transaminases are advised before initiation of treatment with terbinafine. Terbinafine should be discontinued if biochemical or clinical evidence of liver injury occurs.

Severe neutropenia, Stevens-Johnson syndrome, and toxic epidermal necrolysis have been reported with terbinafine use. If a progressive skin rash occurs, treatment with terbinafine should be discontinued.

voriconazole (Vfend)⁵⁵

Coadministration of voriconazole is contraindicated with CYP3A4 substrates including terfenadine, astemizole, cisapride, pimozide, or quinidine because increased plasma concentrations of these drugs can lead to QTc prolongation and rare occurrences of torsades de pointes. Voriconazole should not be given concurrently with sirolimus (increased sirolimus concentrations), rifampin, carbamazepine, and long-acting barbiturates (decreased voriconazole concentrations), high-dose ritonavir 400 mg every 12 hours (decreased voriconazole concentrations), and St. John's Wort. Use caution when administering efavirenz and voriconazole (decreased voriconazole concentrations and increased efavirenz concentrations). Additionally, voriconazole should not be given with rifabutin as voriconazole concentrations are decreased and rifabutin concentrations are increased. Ergot alkaloids should not be used with voriconazole.

Voriconazole prescribing information should be consulted for a detailed description of drug interactions and required dosage modifications prior to initiating therapy. Monitoring liver enzymes before and during therapy is recommended. Visual disturbances associated with therapy have not been studied beyond 28 days. Electrolyte disturbances including hypokalemia, hypomagnesemia, and hypocalcemia should be corrected prior to initiation of therapy with voriconazole as electrolyte disturbances increase the risk of cardiac arrhythmias.

As with other azole antifungals, hypersensitivity to voriconazole or any of the excipients contraindicates its use. There is no information regarding cross-sensitivity among voriconazole and other azole antifungal agents.

Voriconazole is associated with rare cases of serious hepatic reactions including clinical hepatitis, cholestasis, and fulminant hepatic failure with fatalities. Severe hepatic reactions have occurred in patients with serious underlying medical conditions, predominantly hematological malignancy. Hepatic reactions such as hepatitis and jaundice have occurred in patients with no identifiable risk factors. Liver dysfunction was reversible after discontinuation of voriconazole in most cases. Liver function tests should be performed prior to voriconazole therapy and during therapy to monitor for hepatic injury.

Voriconazole tablets contain lactose and should not be given to patients with rare hereditary problems of galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.

Drug Interactions

Numerous drug interactions are associated with antifungal agents. See chart on next page.

Due to low systemic absorption, drug interactions with clotrimazole (Mycelex) and nystatin are limited.^{56,57}

Posaconazole (Noxafil) is primarily metabolized via UDP glucuronidation (phase 2 enzymes) and is a substrate for p-glycoprotein (P-gp) efflux.⁵⁸ Therefore, inhibitors or inducers of these clearance pathways may affect posaconazole plasma concentrations. The UDP inducers include efavirenz, rifabutin, and phenytoin. The UDP inducers reduce C_{max} and area under the curve (AUC) of posaconazole, thus reducing bioavailability. Avoid concurrent use with efavirenz, rifabutin, or phenytoin unless the benefit outweighs the risk.

Patients should be monitored for breakthrough fungal infections while on posaconazole when concurrently taking esomeprazole or cimetidine (due to an increase in gastric pH) as well as metoclopramide (due to an increase in gastrointestinal motility). Esomeprazole and metoclopramide have each shown to reduce C_{max} and AUC of posaconazole. Other PPIs have not been studied in combination with esomeprazole.

No clinically relevant effect on posaconazole bioavailability and/or plasma concentrations was observed when administered with an antacid, glipizide, ritonavir, loperamide, or H₂-receptor antagonists other than cimetidine; therefore, no posaconazole dose adjustments are required when used concomitantly with these products.

Concomitant administration of digoxin and itraconazole has led to increased plasma concentrations of digoxin.⁵⁹ Fentanyl plasma concentrations could be increased or prolonged by concomitant use of itraconazole and may cause potentially fatal respiratory depression.

Below is a list of common substrates for CYP 450 enzymes affected by oral antifungal agents.

- Selected substrates for the 2C9 system: diazepam, phenytoin, S-warfarin
- Selected substrates for the 2C19 system: phenytoin, thioridazine
- Selected substrates for the 2D6 system: carvedilol, clozapine, cyclobenzaprine, donepezil, flecainide, fluphenazine, fluoxetine, galantamine, haloperidol, hydrocodone, maprotiline, meperidine, methadone, methamphetamine, metoprolol, mexiletine, morphine, paroxetine, perphenazine, propafenone, propranolol, risperidone, thioridazine, timolol, tramadol, trazodone, and venlafaxine
- Selected substrates for the 3A4 system: triazolam, alprazolam, diazepam, atorvastatin, lovastatin, simvastatin, cyclosporine, tacrolimus, buspirone, terfenadine, astemizole, cisapride, and pimozide

Drug Interactions (continued)

Consult package inserts for detailed information.

Drug	CYP 450 enzyme inhibition	Contraindications	Dose adjustments needed	Monitoring of other drug effects
fluconazole (Diflucan) ⁶⁰	2C9, 3A4	terfenadine cisapride	renal impairment rifampin	cyclosporine warfarin phenytoin sulfonylureas theophylline
flucytosine (Ancobon) ⁶¹	--	--	renal impairment; drugs which reduce GFR	--
griseofulvin (Grifulvin V, Gris-PEG) ⁶²	--	--	long-acting barbiturates	warfarin cyclosporine
itraconazole (Sporanox) ⁶³	3A4	cisapride oral midazolam pimozide quinidine dofetilide nisoldipine triazolam levomethadyl ergot alkaloids lovastatin simvastatin	Decreases elimination of drugs metabolized by CYP3A4; dosing modification is required. See package insert for complete detailed drug list.	See package insert for full details
ketoconazole (Nizoral) ⁶⁴	3A4	astemizole terfenadine cisapride triazolam rifampin isoniazid	cyclosporine tacrolimus methylprednisolone midazolam	digoxin warfarin sulfonylureas phenytoin
posaconazole (Noxafil) ⁶⁵	3A4	terfenadine astemizole pimozide cisapride quinidine ergot alkaloids halofantrine sirolimus	vinca alkaloids statins (3A4 inhibitors) calcium channel blockers (3A4 inhibitors) cyclosporine tacrolimus midazolam phenytoin	cimetidine cyclosporine tacrolimus rifabutin midazolam phenytoin ritonavir atazanavir efavirenz digoxin esomeprazole metoclopramide
terbinafine (Lamisil, Lamisil Granules, Terbinex) ^{66,67}	2D6	--	TCA's, SSRIs, beta-blockers, monoamine oxidase inhibitors—type b rifampin	warfarin
voriconazole (Vfend) ⁶⁸	2C19, 2C9,3A4	rifampin ritonavir (high dose) carbamazepine long-acting barbiturates rifabutin sirolimus terfenadine astemizole cisapride pimozide quinidine ergot alkaloids St. John's Wort	cyclosporine tacrolimus statins (3A4 inhibitors) benzodiazepines (midazolam, triazolam, alprazolam) calcium channel blockers phenytoin omeprazole vinca alkaloids methadone alfentanil efavirenz	warfarin coumarin derivatives sulfonylureas protease inhibitors non-nucleoside reverse transcriptase inhibitors oral contraceptives with ethinyl estradiol and norethindrone ritonavir (low-dose)

Adverse Effects

Drug	Nausea	Headache	Rash	Vomiting	Abd. pain	Diarrhea	Pruritus	Elevated LFT
clotrimazole (Mycelex troche) ⁶⁹	reported	nr	nr	reported	nr	nr	reported	15
fluconazole (Diflucan) ⁷⁰ n=4,048	3.7	1.9	1.8	1.7	1.7	1.5	nr	reported
flucytosine (Ancobon) ⁷¹	reported	reported	reported	reported	reported	reported	nr	reported
griseofulvin (Grifulvin V, Gris-PEG) ^{72,73}	reported	reported	reported	reported	nr	reported	nr	reported
itraconazole (Sporanox) ⁷⁴ n=112 200 mg daily X 12 wks	3	10	4	reported	4	4	reported	4
ketoconazole (Nizoral) ⁷⁵	3	<1	nr	3	1.2	< 1	1.5	reported
nystatin (Mycostatin) ⁷⁶	reported	nr	nr	reported	reported	reported	nr	nr
posaconazole (Noxafil) ⁷⁷	9	8	3	7	5	10	nr	1/1
fluconazole (oral pharyngeal candidiasis)	11	9	4	7	6	13		2/2
terbinafine (Lamisil, Terbinex) ^{78,79} n=465	2.6 (2.9)	12.9 (9.5)	5.6 (2.2)	reported	2.4 (1.5)	5.6 (2.9)	2.8 (1.5)	3.3 (1.4)
terbinafine (Lamisil Granules) ⁸⁰ n=1,042	2	7	2	5	2-4	3	1	nr
voriconazole (Vfend) ⁸¹ n=1,655	5.4	3	5.3-7	4.4	< 2	< 2	< 2	2.7-12.4

Incidence is reported as a percentage. Adverse events data are obtained from prescribing information and therefore should not be considered comparative. Incidences for placebo indicated in parentheses. nr = not reported

Voriconazole is reported to be associated with abnormal visual disturbances (15.5 percent oral therapy and 21 percent IV and oral therapy), which resolve with discontinuation of therapy.⁸²

In patients with normal gastrointestinal, renal, and hematologic function, flucytosine is generally associated with few adverse events, although rash, GI discomfort, diarrhea (five to 10 percent), and reversible elevations in hepatic enzymes are occasionally observed. In patients with renal dysfunction or in patients on concomitant amphotericin B, leukopenia, thrombocytopenia, and

enterocolitis may occur. Flucytosine is associated with dose-dependent, potentially lethal bone marrow suppression.⁸³

Special Populations^{84,85,86,87,88,89,90,91,92,93}

Pediatrics

Clotrimazole (Mycelex) troches have been used in children ages three years and older. Nystatin (Mycostatin) has been used in infants.⁹⁴ Safety and effectiveness of ketoconazole (Nizoral) have been established for children over two years of age. Terbinafine (Lamisil Granules) is approved for the treatment of tinea capitis for ages four years and older. The safety and efficacy of terbinafine tablets (Terbinex) have not been established in pediatric patients. Eco Formula (component of Terbinex kit) should be kept out of the reach of children. Safety and effectiveness of griseofulvin (Gris-Peg, Grifulvin V) have been established for children over age two years. Fluconazole safety and effectiveness data exist for children older than six months. Intravenous fluconazole has been used in preterm infants; however, efficacy has not been established in infants less than six months of age.⁹⁵

Safety and effectiveness of posaconazole (Noxafil) in pediatric patients less than 13 years of age have not been established. Safety and effectiveness of itraconazole have not been proven in pediatric patients. Voriconazole (Vfend) does not have safety and effectiveness data in children less than 12 years old. Pharmacokinetics and safety data were collected in a small trial with intravenous voriconazole in children ages two to 11 years.⁹⁶

No studies of flucytosine (Ancobon) in pediatric patients exist; however, published reports of use of flucytosine with and without amphotericin B in doses of 25-200 mg/kg per day are available. No unexpected serious adverse effects were reported.

Pregnancy

Terbinafine is Pregnancy Category B. Clotrimazole, flucytosine, posaconazole, fluconazole, itraconazole, ketoconazole, and griseofulvin are Pregnancy Category C. Voriconazole is Pregnancy Category D.

Two cases of conjoined twins have been reported with first trimester use of griseofulvin. Griseofulvin should not be used in pregnant patients. Griseofulvin therapy should be discontinued if the patient becomes pregnant during treatment, and potential hazards to the fetus should be explained.

Elderly

Transient or permanent hearing loss has been reported in elderly patients receiving treatment with itraconazole. Several of these reports included concurrent administration of quinidine which is contraindicated.

Dosages

Drug	Oral Dosage Forms	Adult Dosage
clotrimazole (Mycelex Troche) ⁹⁷	10 mg troche	<ul style="list-style-type: none"> • Treatment: One troche (10 mg) five times per day • Prevention: One troche (10 mg) three times per day
fluconazole (Diflucan) ⁹⁸	50, 100, 150, 200 mg tablets 10 mg/mL, 40 mg/mL suspension	<ul style="list-style-type: none"> • Oral and esophageal candidiasis: 200 mg X 1, then 100 mg daily • Vaginal candidiasis: 150 mg orally X 1 • Urinary tract infections and peritonitis: 50 to 200 mg daily • Cryptococcal meningitis: 400 mg X 1, then 200 mg daily • Undergoing bone marrow transplant: 400 mg daily until neutrophils >1,000 cells/m³ for seven days
flucytosine (Ancobon) ⁹⁹	250, 500 mg capsules	<ul style="list-style-type: none"> • 50 – 150 mg/kg/day in divided doses every six hours
griseofulvin (Grifulvin V, Gris-PEG) ^{100,101}	<u>Microsized:</u> Grifulvin V: 125 mg/5 mL suspension; 250, 500 mg tablets <u>Ultramicrosized:</u> Gris-PEG: 125, 250 mg tablets	<p><u>Microsized:</u></p> <ul style="list-style-type: none"> • Onychomycosis (toenail): 750 mg once daily or in two to four divided doses for at least six months • Other tinea infections: 500 mg orally once daily or in two to four divided doses per day. <p><u>Ultramicrosized:</u></p> <ul style="list-style-type: none"> • Onychomycosis (toenail): 750 mg once daily – as a single dose or in divided doses for at least six months • Other tinea infections: 375 mg orally once daily or in two to four divided doses per day <p>Treatment durations are as follows: tinea capitis, four to six weeks; tinea corporis, two to four weeks; tinea pedis, four to eight weeks.</p>
itraconazole (Sporanox) ¹⁰²	100 mg capsule 10 mg/mL solution	<ul style="list-style-type: none"> • Onychomycosis (toenail): 200 mg daily for 12 weeks • Onychomycosis (fingernail): two treatment pulses, which consist of 200 mg twice daily for one week. The pulses are separated by a three-week period without itraconazole. • Treatment of Blastomycosis, Histoplasmosis: 200 mg daily • Treatment of Aspergillosis: 200 to 400 mg daily
ketoconazole (Nizoral) ¹⁰³	200 mg tablet	<ul style="list-style-type: none"> • 200 to 400 mg daily
nystatin (Mycostatin) ¹⁰⁴	Variety of dosage forms and strengths	<ul style="list-style-type: none"> • Intestinal and oral candidiasis 400,000 to 600,000 units four times daily
posaconazole (Noxafil) ¹⁰⁵	200 mg/5 mL oral suspension	<ul style="list-style-type: none"> • Prophylaxis of invasive fungal Infections: 200 mg (5 mL) three times daily during or immediately following (within 20 minutes) a full meal or with a liquid nutritional supplement in patients who can not eat a full meal. Duration of therapy is based on recovery from neutropenia or immunosuppression. • Oropharyngeal candidiasis: Loading dose of 100 mg twice daily on day 1 then 100 mg once daily for 13 days. • Oropharyngeal candidiasis refractory to fluconazole and/or itraconazole: 400 mg twice daily. Duration to be determined by patient's severity of underlying disease and clinical response.
terbinafine (Lamisil, Lamisil Granules) ^{106,107}	250 mg tablet	<ul style="list-style-type: none"> • Onychomycosis (toenail): 250 mg daily for 12 weeks • Onychomycosis (fingernail): 250 mg daily for six weeks
terbinafine (Terbinex) ¹⁰⁸	250 mg tablet	<ul style="list-style-type: none"> • Onychomycosis (toenail): 250 mg daily for 12 weeks • Onychomycosis (fingernail): 250 mg daily for six weeks • A thin layer of EcoFormula should be applied daily to clean, dry nails preferably before bedtime.

Dosages (continued)

Drug	Oral Dosage Forms	Adult Dosage
voriconazole (Vfend) ¹⁰⁹	50, 200 mg tablets 200 mg/5 mL suspension	<p><u>IV</u>: (IV load is required to initiate therapy for all infections except esophageal candidiasis)</p> <ul style="list-style-type: none"> 6 mg/kg every 12 hours X two doses then 4 mg/kg every 12 hours <u>Oral</u>: > 40 kg: 200 mg every 12 hours < 40 kg: 100 mg every 12 hours <u>Concurrent phenytoin therapy</u>: IV: 5 mg/kg every 12 hours Oral: > 40 kg: 400 mg every 12 hours < 40 kg: 200 mg every 12 hours <p>Oral voriconazole should be taken one hour before or one hour after a meal.</p>

Dosage recommendations for pediatric patients are listed below.

Drug	Oral Dosage Forms	Ages	Pediatric Dosage								
clotrimazole (Mycelex Troche) ¹¹⁰	10 mg troche	> three years	<ul style="list-style-type: none"> Oropharyngeal candidiasis: One troche (10 mg) five times per day 								
fluconazole (Diflucan) ¹¹¹	50, 100, 150, 200 mg tablets 10 mg/mL, 40 mg/mL suspension	six months to 13 years	<ul style="list-style-type: none"> Oral candidiasis: 6mg/kg X 1; then 3 mg/kg daily for at least two weeks Esophageal candidiasis: 6 mg/kg X 1; then 3 mg/kg daily for at least three weeks Cryptococcal meningitis: 12 mg/kg X 1; then 6 to 12 mg/kg daily Systemic infections: 6 to 12 mg/kg daily Equivalent dosing <table border="1"> <thead> <tr> <th>Pediatric dose</th> <th>Adult dose</th> </tr> </thead> <tbody> <tr> <td>3 mg/kg daily</td> <td>100 mg daily</td> </tr> <tr> <td>6 mg/kg daily</td> <td>200 mg daily</td> </tr> <tr> <td>12 mg/kg daily</td> <td>400 mg daily</td> </tr> </tbody> </table> <ul style="list-style-type: none"> Pediatric dose should not exceed 600 mg daily. 	Pediatric dose	Adult dose	3 mg/kg daily	100 mg daily	6 mg/kg daily	200 mg daily	12 mg/kg daily	400 mg daily
Pediatric dose	Adult dose										
3 mg/kg daily	100 mg daily										
6 mg/kg daily	200 mg daily										
12 mg/kg daily	400 mg daily										
Griseofulvin (Grifulvin V, Gris-PEG) ^{112,113}	<p><u>Microsized</u>: Grifulvin V: 125 mg/5 mL suspension; 250, 500 mg tablets</p> <p><u>Ultramicrosized</u>: Gris-PEG: 125, 250 mg tablets</p>	> two years	<p><u>Microsized</u>:</p> <ul style="list-style-type: none"> Pediatrics: 10-20 mg/kg daily (max: 1 g) given in one to two divided doses <p><u>Ultramicrosized</u>:</p> <ul style="list-style-type: none"> Pediatrics: 3.3-7.3 mg/kg/day 								
ketoconazole (Nizoral) ¹¹⁴	200 mg tablet	> two years	<ul style="list-style-type: none"> 3.3-6.6 mg/kg/day 								
nystatin (Mycostatin) ¹¹⁵	various	neonates and older	<ul style="list-style-type: none"> Intestinal and oral candidiasis: 100,000 to 600,000 units four times daily 								
terbinafine (Lamisil Granules) ¹¹⁶	125 mg packet 187.5 mg packet	> four years	<ul style="list-style-type: none"> Tinea capitis: Dose, based on body weight, given once daily for six weeks: <table border="1"> <thead> <tr> <th>Weight</th> <th>Dose</th> </tr> </thead> <tbody> <tr> <td>< 25 kg</td> <td>125 mg</td> </tr> <tr> <td>25-35 kg</td> <td>187.5 mg</td> </tr> <tr> <td>> 35 kg</td> <td>250 mg</td> </tr> </tbody> </table> <p>Sprinkle contents of pack on a spoonful of pudding or other soft non-acidic food such as mashed potatoes. Do not use apple sauce or fruit-based foods. Swallow entire spoonful without chewing. Take with food.</p>	Weight	Dose	< 25 kg	125 mg	25-35 kg	187.5 mg	> 35 kg	250 mg
Weight	Dose										
< 25 kg	125 mg										
25-35 kg	187.5 mg										
> 35 kg	250 mg										

Clinical Trials

Search Strategy

Articles were identified through searches performed on PubMed and review of information sent by manufacturers. Search strategy included the FDA-approved use of all drugs in this class. Randomized, controlled, comparative trials of oral agents used in the outpatient setting are considered the most relevant in this category. Many of the more recent studies have focused on inpatient use of the antifungal agents. Studies included for analysis in the review were published in English, performed with human participants, and randomly allocated participants to comparison groups. In addition, studies must contain clearly stated, predetermined outcome measure(s) of known or probable clinical importance, use data analysis techniques consistent with the study question, and include follow-up (endpoint assessment) of at least 80 percent of participants entering the investigation. Despite some inherent bias found in all studies including those sponsored and/or funded by pharmaceutical manufacturers, the studies in this therapeutic class review were determined to have results or conclusions that do not suggest systematic error in their experimental study design. While the potential influence of manufacturer sponsorship/funding must be considered, the studies in this review have also been evaluated for validity and importance. No clinical trials evaluating the Terbinex kit have been published.

fluconazole (Diflucan) and voriconazole (Vfend) – esophageal candidiasis

In a double-blind, placebo-controlled trial, 256 immunocompromised patients, most of whom were HIV-positive with biopsy-proven esophageal candidiasis, were randomized to voriconazole (400 mg for one dose; then 200 mg twice daily), fluconazole (400 mg for one dose; then 200 mg daily), or placebo. The study evaluated efficacy, tolerability, and safety.¹¹⁷ Patients were on therapy for at least seven days after clinical signs and symptoms resolved or for a maximum of six weeks. Patients underwent endoscopy at day 43 to determine efficacy. Endoscopy-documented success (98.3 percent versus 95.1 percent, respectively) as well as symptomatic success (88 percent versus 91.1 percent, respectively) was similar between voriconazole and fluconazole. Visual disturbances were reported in 18 percent of voriconazole patients compared to five percent with fluconazole. More patients discontinued voriconazole due to laboratory abnormalities or treatment-related adverse effects.

griseofulvin oral suspension and terbinafine granules (Lamisil Granules) – tinea capitis

Terbinafine oral granules and griseofulvin oral suspension were compared for efficacy and safety in the treatment of tinea capitis in children ages four to 12 years in two investigator-blinded studies.¹¹⁸ Patients were randomized to terbinafine 5-8 mg/kg daily or griseofulvin 10-20 mg/kg for six weeks of treatment. The 1,549 patients were followed for an additional four weeks. End of study complete cure was defined as a negative fungal culture and microscopy with no symptoms. Mycologic cure was defined as negative fungal culture and microscopy. Clinical cure was the absence of symptoms. The pooled intent-to-treat population consisted of 1,286 patients. Rates of complete cure and mycologic cure were significantly higher for terbinafine than for griseofulvin (45.1 versus 39.2 percent and 61.5 versus 55.5 percent, respectively; each $p < 0.05$). Most griseofulvin patients (86.7 percent) received 10 to 19.9 mg/kg per day; complete cure rate was not found to be higher among patients who received more than griseofulvin 20 mg/kg per day compared with those who received less than 20 mg/kg per day. Complete cure rate was statistically significantly greater for terbinafine compared to griseofulvin in trial 1 (46.23 versus 34.01 percent, respectively) but not in trial 2 (43.99 versus 43.46 percent, respectively). Clinical cure was similar between the two drugs based on the pooled data. Subgroup analyses revealed that terbinafine was significantly better than griseofulvin for all cure rates among patients with *Trichophyton tonsurans* but not *Microsporum canis* ($p < 0.001$). For *M. canis*,

mycologic and clinical cure rates were significantly better with griseofulvin than with terbinafine ($p < 0.05$). Therapies were well tolerated.

terbinafine (Lamisil) versus itraconazole (Sporanox) - onychomycosis

In a prospective, randomized, double-blind, multicenter study, researchers compared the efficacy and tolerability of continuous terbinafine with intermittent itraconazole for treatment of toenail onychomycosis.¹¹⁹ The study included 496 patients diagnosed with toenail onychomycosis caused by a dermatophyte. Patients were randomly assigned to four parallel groups: terbinafine 250 mg per day for 12 or 16 weeks or itraconazole 400 mg per day for one week in every four weeks for 12 or 16 weeks. The primary outcome measure was mycological cure, defined as negative microscopy and negative culture of samples from the target toenail. At week 72, mycological cure rates were 75.5 percent in the 12-week terbinafine group and 80.8 percent in the 16-week terbinafine group, compared with 38.3 percent in the itraconazole 12-week study group and 49.1 percent in the itraconazole 16-week group. All treatments were well tolerated, with no significant differences in the number or type of adverse events reported. Researchers concluded continuous terbinafine is more effective than intermittent itraconazole for the treatment of toenail onychomycosis.

In a five-year, blinded, prospective follow-up study to the aforementioned study, the long-term effectiveness of terbinafine was compared to itraconazole in 151 patients.¹²⁰ At the end of five years, mycologic cure achieved with one treatment course was found in 46 percent and 13 percent of the terbinafine-treated and itraconazole-treated patients, respectively ($p < 0.001$). Mycologic and clinical relapse rates were significantly higher in the itraconazole-treated group, 53 percent and 48 percent, respectively, compared to the terbinafine-treated group, 23 percent and 21 percent, respectively.

posaconazole (Noxafil), fluconazole (Diflucan) and/or itraconazole (Sporanox)

Due to the lack of other comparative data with posaconazole, this study is included in the review. In a randomized, multicenter study, safety and efficacy of posaconazole ($n=304$), fluconazole ($n=240$), and itraconazole ($n=58$) were compared for invasive fungal infection prophylaxis in patients with prolonged neutropenia.¹²¹ Patients were undergoing treatment for acute myelogenous leukemia or myelodysplastic syndrome. In this investigator-blinded study, patients received prophylaxis with the assigned treatment with each cycle of chemotherapy until recovery from neutropenia and complete remission occurred or until the occurrence of an invasive fungal infection or for up to 12 weeks. Proven or probable invasive fungal infections were reported in two percent of the posaconazole group and eight percent in the fluconazole or itraconazole group (absolute reduction, 6 percent; 95% CI, -9.7 to -2.5; $p < 0.001$). Invasive aspergillosis was significantly lower in the posaconazole group (one percent versus seven percent, $p < 0.001$). Survival was significantly higher in the posaconazole group (16 percent mortality) than in the fluconazole/itraconazole group (22 percent mortality, $p = 0.04$). Serious adverse effects were significantly more common in the posaconazole group (six percent versus two percent; $p = 0.01$). The most common adverse effects related to the gastrointestinal tract.

In a multicenter, randomized, double-blind trial, oral posaconazole and fluconazole were compared for prophylaxis against invasive fungal infections in patients with graft-versus-host disease (GVHD) who were receiving immunosuppressive therapy.¹²² Six hundred allogeneic hematopoietic stem-cell transplant patients were enrolled. At the end of the 112-day treatment period, posaconazole and fluconazole were similarly effective in preventing all invasive fungal infections (5.3 and 9 percent, respectively; odds ratio=0.56; 95% CI, 0.30 to 1.07, $p = 0.07$). Posaconazole was superior to fluconazole in preventing proven or probable invasive

aspergillosis (2.3 and 7 percent, odds ratio=0.31, 95% CI, 0.13 to 0.75, p=0.006). Overall mortality was similar in the two groups; however, the number of deaths from invasive fungal infections was lower in the posaconazole group (1 and 4 percent, p=0.046). Treatment-related adverse effects were similar in both groups (36 percent for posaconazole and 38 percent for fluconazole).

Due to the lack of other comparative data with posaconazole, this study is included in the review. Posaconazole was compared to fluconazole in a multicenter, randomized, single-blinded trial evaluating efficacy and safety in the treatment of oropharyngeal candidiasis in patients with HIV/AIDS.¹²³ Patients (n=350) were randomized to posaconazole or fluconazole 200 mg on day one then 100 mg daily for 13 days. Clinical success, defined as cure or improvement on day 14, was observed in 91.7 and 92.5 percent for posaconazole and fluconazole groups, respectively (95% CI, -6.61 to 5.04). Mycological success was 68 percent in both arms on day 14, but mycological success on day 42 was 40.6 and 26.4 percent for posaconazole and fluconazole, respectively (p=0.038). Clinical relapse rates were 31.5 percent for posaconazole and 38.2 percent for fluconazole. Adverse effects were similar.

Meta-Analysis

A meta-analysis determined mycological cure rate in randomized clinical trials is consistently 76 percent for terbinafine (Lamisil) and 63 percent for pulse dose itraconazole (Sporanox).¹²⁴ Thirty-six randomized, controlled trials evaluated the efficacy of terbinafine, itraconazole, fluconazole (Diflucan), and griseofulvin (Grifulvin V, Gris-PEG) in the treatment of dermatophyte toenail onychomycosis.¹²⁵ Studies were required to use a standard dosage regimen (pulse or continuous), treatment duration, and follow-up period. Mycological and clinical response rates were compared for the randomized controlled trials and open trials for each of the agents. Studies were pooled from earliest (1966) to most recent to determine the cumulative meta-analytical average. The overall cumulative meta-average for mycological cure rates were terbinafine 76 ± 3 percent (18 studies), itraconazole pulse 63 ± 7 percent (six studies), itraconazole continuous 59 ± 5 percent (seven studies), fluconazole 48 ± 5 percent (three studies), and griseofulvin 60 ± 6 percent (three studies). When comparing randomized controlled trials and open-label trials, the cumulative meta-analytical average for mycological cure rates were significantly higher in the open-label trials for terbinafine, itraconazole pulse dose, and fluconazole.

Randomized controlled trials (21 studies) that evaluated systemic antifungal therapy for tinea capitis in immunocompetent children (n=1,812) were identified.¹²⁶ All studies required a tinea capitis diagnosis to be confirmed by microscopy or growth of dermatophytes in culture or both. For infections caused by *Trichophyton* species, terbinafine for four weeks and griseofulvin for eight weeks showed similar efficacy (RR 1.09; 95% CI, 0.95 to 1.26). Two studies found cure rates to be similar following treatment with itraconazole and griseofulvin for six weeks. There was no difference between itraconazole and terbinafine for treatment periods lasting two to three weeks in two studies involving 160 children (RR 0.93; 95% CI, 0.72 to 1.19). Two studies that included 140 children found similar cure rates between two to four weeks of fluconazole with six weeks of griseofulvin (RR 0.92; 95% CI, 0.8 to 1.05). For *Microsporum* infections, no significant difference in cure rates were observed between terbinafine and griseofulvin, based on one small study of 29 children (RR 0.64; 95% CI, 0.19 to 2.20). Shorter treatment durations may improve treatment adherence.

In a Cochrane review of agents to treat oral candidiasis in cancer patients, ketoconazole (Nizoral) proved a more reliable agent than clotrimazole (Mycelex) based on a total of eight

randomized controlled clinical trials including 418 patients.¹²⁷ A recent Cochrane review found very few comparative trials on which to evaluate efficacy of prophylaxis of oropharyngeal candidiasis in HIV-positive patients.¹²⁸ It appeared that ketoconazole, fluconazole, itraconazole, and clotrimazole improved treatment outcomes in the treatment of oropharyngeal candidiasis.

A meta-analysis compared griseofulvin (Grifulvin V, Gris-PEG) and terbinafine in the treatment of tinea capitis in children.¹²⁹ Randomized, clinical studies with treatment for at least six weeks were included. Identification of the dermatophyte was required for inclusion. A total of six trials were evaluated. Outcome parameters were compared at 12 to 16 weeks after enrollment. The common odds ratio was 0.86, which tells us that the studies included had similar outcomes. When *Trichophyton* species were isolated in studies looking at outcomes at 12 weeks, the results trended toward terbinafine. Outcomes after eight weeks for both treatments were similar. Authors concluded terbinafine for two to four weeks is at least as effective as griseofulvin for at least six weeks for *Trichophyton* infections of the scalp. With other pathogens, griseofulvin may be a superior agent.

Another meta-analysis evaluated seven trials with griseofulvin for the treatment of tinea capitis. Overall cure rate after four to six weeks post-treatment was 73.4 percent (seven studies; n=438 patients).¹³⁰ Higher efficacy rates were reported with the use of higher dosages of griseofulvin (>18 mg/kg/day). When broken down by species, the mean efficacy for *Trichophyton* and *Microsporum* were 67.6 percent (five studies, n=396) and 88.1 percent (two studies, n=42 patients), respectively.

Summary

Oral antifungals used in the outpatient setting generally treat fungal infections such as oropharyngeal candidiasis, urinary tract infections, superficial skin infections, and onychomycosis. Due to its excellent penetration into many tissues, fluconazole (Diflucan) is effective *Candida* treatment for a variety of infections, lacking concerns about pH-dependent absorption such as that seen with ketoconazole (Nizoral). Effective therapy for oropharyngeal candidiasis includes fluconazole, itraconazole, ketoconazole, nystatin, and clotrimazole troches (Mycelex). Voriconazole (Vfend) has been shown to have similar efficacy to fluconazole in the treatment of esophageal candidiasis; however, more adverse effects are reported with voriconazole. Posaconazole (Noxafil) has an indication for treatment of oropharyngeal candidiasis when refractory to itraconazole and/or fluconazole. Nystatin is also used to treat intestinal candidiasis and may be used in infants and children.

In comparative trials, terbinafine (Lamisil) demonstrated higher treatment success rates of toenail onychomycosis in immunocompetent patients compared to itraconazole (Sporanox). Terbinafine also demonstrated higher clinical success rates in the treatment of tinea capitis than griseofulvin (Grifulvin V, Gris-PEG), however, griseofulvin had higher success rates in those infections caused by *Microsporum*.

Utility of griseofulvin for treatment of onychomycosis has decreased since the introduction of the azole antifungals and terbinafine. Duration of therapy is often longer than with other agents, which may result in increased adverse effects and require monitoring of liver, renal, and hematopoietic function. However, griseofulvin is still a useful agent in the treatment of many fungal skin infections that do not respond to topical therapies.

For serious fungal infections, posaconazole, flucytosine (Ancobon), voriconazole, itraconazole, and fluconazole have indications for the treatment and/or prophylaxis of various serious fungal infections.

References

- ¹ Mycelex troche [package insert]. Mountain View, CA; Alza Corporation; February 2003.
- ² Diflucan [package insert]. New York, NY; Pfizer; March 2008.
- ³ Ancobon [package insert]. Alisa Viejo, CA; Valeant; January 2008.
- ⁴ Available at <http://www.clinicalpharmacology.com>. Accessed January 12, 2010.
- ⁵ Grifulvin V [package insert]. Raritan, NJ; Ortho; January 1997.
- ⁶ Gris-PEG [package insert]. Farmingdale, NY; Pedinol Pharmacal; January 2007.
- ⁷ Sporanox [package insert]. Raritan, NJ; Pricara; March 2009.
- ⁸ Nizoral [package insert]. Titusville, NJ; Janssen; 1998.
- ⁹ Available at <http://www.clinicalpharmacology.com>. Accessed January 12, 2010.
- ¹⁰ Noxafil [package insert]. Kenilworth, NJ; Schering Corp; December 2008.
- ¹¹ Lamisil [package insert]. East Hanover, NJ; Novartis Pharmaceuticals Corporation; March 2004.
- ¹² Lamisil Granules [package insert]. East Hanover, NJ; Novartis Pharmaceuticals Corporation; September 2007.
- ¹³ Terbinex [package insert]. Charleston, SC; JSJ Pharmaceuticals; June 2009.
- ¹⁴ Vfend [package insert]. New York, NY; Pfizer; May 2008.
- ¹⁵ Pappas PG, Kauffman CA, Andes D, et al. Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America. Clin Inf Dis. 2009; 48:503–35.
- ¹⁶ Mofenson LM, Brady MT, Danner SP, et al. Centers for Disease Control and Prevention, National Institutes of Health, HIV Medicine Association of the Infectious Diseases Society of America, Pediatric Infectious Diseases Society, American Academy of Pediatrics. Fungal infections. In: Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association. MMWR Recomm Rep. 2009; 58(RR-11):28-50.
- ¹⁷ Pappas PG, Kauffman CA, Andes D, et al. Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America. Clin Inf Dis. 2009; 48:503–35.
- ¹⁸ Mofenson LM, Brady MT, Danner SP, et al. Centers for Disease Control and Prevention, National Institutes of Health, HIV Medicine Association of the Infectious Diseases Society of America, Pediatric Infectious Diseases Society, American Academy of Pediatrics. Fungal infections. In: Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association. MMWR Recomm Rep. 2009; 58(RR-11):28-50.
- ¹⁹ Scher RK, Baran R. Onychomycosis in clinical practice: factors contributing to recurrence. Br J Dermatol. 2003; 149(Suppl 65):5-9.
- ²⁰ Mycelex troche [package insert]. Mountain View, CA; Alza Corporation; February 2003.
- ²¹ Diflucan [package insert]. New York, NY; Pfizer; March 2008.
- ²² Ancobon [package insert]. Alisa Viejo, CA; Valeant; January 2008.
- ²³ Available at <http://www.clinicalpharmacology.com>. Accessed January 12, 2010.
- ²⁴ Sporanox [package insert]. Raritan, NJ; Pricara; March 2009.
- ²⁵ Nizoral [package insert]. Titusville, NJ; Janssen; 1998.
- ²⁶ Available at <http://www.clinicalpharmacology.com>. Accessed January 12, 2010.
- ²⁷ Noxafil [package insert]. Kenilworth, NJ; Schering Corp; December 2008.
- ²⁸ Lamisil [package insert]. East Hanover, NJ; Novartis Pharmaceuticals Corporation; March 2004.
- ²⁹ Lamisil Granules [package insert]. East Hanover, NJ; Novartis Pharmaceuticals Corporation; September 2007.
- ³⁰ Terbinex [package insert]. Charleston, SC; JSJ Pharmaceuticals; June 2009.
- ³¹ Vfend [package insert]. New York, NY; Pfizer; May 2008.
- ³² Mycelex troche [package insert]. Mountain View, CA; Alza Corporation; February 2003.
- ³³ Diflucan [package insert]. New York, NY; Pfizer; March 2008.
- ³⁴ Ancobon [package insert]. Alisa Viejo, CA; Valeant; January 2008.
- ³⁵ Available at <http://www.clinicalpharmacology.com>. Accessed January 12, 2010.
- ³⁶ Sporanox [package insert]. Raritan, NJ; Pricara; March 2009.
- ³⁷ Nizoral [package insert]. Titusville, NJ; Janssen; 1998.
- ³⁸ Available at <http://www.clinicalpharmacology.com>. Accessed January 12, 2010.
- ³⁹ Noxafil [package insert]. Kenilworth, NJ; Schering Corp; December 2008.
- ⁴⁰ Lamisil [package insert]. East Hanover, NJ; Novartis Pharmaceuticals Corporation; March 2004.
- ⁴¹ Terbinex [package insert]. Charleston, SC; JSJ Pharmaceuticals; June 2009.
- ⁴² Lamisil Granules [package insert]. East Hanover, NJ; Novartis Pharmaceuticals Corporation; September 2007.
- ⁴³ Vfend [package insert]. New York, NY; Pfizer; May 2008.
- ⁴⁴ Mycelex troche [package insert]. Mountain View, CA; Alza Corporation; February 2003.
- ⁴⁵ Diflucan [package insert]. New York, NY; Pfizer; March 2008.
- ⁴⁶ Ancobon [package insert]. Alisa Viejo, CA; Valeant; January 2008.
- ⁴⁷ Gris-PEG [package insert]. Farmingdale, NY; Pedinol Pharmacal; January 2007.
- ⁴⁸ Sporanox [package insert]. Raritan, NJ; Pricara; March 2009.
- ⁴⁹ Available at <http://www.clinicalpharmacology.com>. Accessed January 12, 2010.
- ⁵⁰ Nizoral [package insert]. Titusville, NJ; Janssen; July 1998.
- ⁵¹ Noxafil [package insert]. Kenilworth, NJ; Schering Corp; December 2008.
- ⁵² Sporanox [package insert]. Raritan, NJ; Pricara; March 2009.
- ⁵³ Lamisil [package insert]. East Hanover, NJ; Novartis Pharmaceuticals Corporation; March 2004.
- ⁵⁴ Terbinex [package insert]. Charleston, SC; JSJ Pharmaceuticals; June 2009.
- ⁵⁵ Vfend [package insert]. New York, NY; Pfizer; May 2008.
- ⁵⁶ Mycelex troche [package insert]. Mountain View, CA; Alza Corporation; February 2003.

- ⁵⁷ Available at <http://www.clinicalpharmacology.com>. Accessed January 12, 2010.
- ⁵⁸ Noxafil [package insert]. Kenilworth, NJ; Schering Corp; December 2008.
- ⁵⁹ Sporanox [package insert]. Raritan, NJ; Pricara; March 2009.
- ⁶⁰ Diflucan [package insert]. New York, NY; Pfizer; March 2008.
- ⁶¹ Ancobon [package insert]. Alisa Viejo, CA; Valeant; January 2008.
- ⁶² Gris-PEG [package insert]. Farmingdale, NY; Pedinol Pharmcal; January 2007.
- ⁶³ Sporanox [package insert]. Raritan, NJ; Pricara; March 2009.
- ⁶⁴ Nizoral [package insert]. Titusville, NJ; Janssen; 1998.
- ⁶⁵ Noxafil [package insert]. Kenilworth, NJ; Schering Corp; December 2008.
- ⁶⁶ Lamisil [package insert]. East Hanover, NJ; Novartis Pharmaceuticals Corporation; March 2004.
- ⁶⁷ Terbinex [package insert]. Charleston, SC; JSJ Pharmaceuticals; June 2009.
- ⁶⁸ Vfend [package insert]. New York, NY; Pfizer; May 2008.
- ⁶⁹ Mycelex troche [package insert]. Mountain View, CA; Alza Corporation; February 2003.
- ⁷⁰ Diflucan [package insert]. New York, NY; Pfizer; March 2008.
- ⁷¹ Ancobon [package insert]. Alisa Viejo, CA; Valeant; January 2008.
- ⁷² Gris-PEG [package insert]. Farmingdale, NY; Pedinol Pharmcal; January 2007.
- ⁷³ Grifulvin V [package insert]. Raritan, NJ; Ortho; January 1997.
- ⁷⁴ Sporanox [package insert]. Raritan, NJ; Pricara; March 2009.
- ⁷⁵ Nizoral [package insert]. Titusville, NJ; Janssen; 1998.
- ⁷⁶ Available at <http://www.clinicalpharmacology.com>. Accessed January 12, 2010.
- ⁷⁷ Noxafil [package insert]. Kenilworth, NJ; Schering Corp; December 2008.
- ⁷⁸ Lamisil [package insert]. East Hanover, NJ; Novartis Pharmaceuticals Corporation; March 2004.
- ⁷⁹ Terbinex [package insert]. Charleston, SC; JSJ Pharmaceuticals; June 2009.
- ⁸⁰ Lamisil [package insert]. East Hanover, NJ; Novartis Pharmaceuticals Corporation; March 2004.
- ⁸¹ Vfend [package insert]. New York, NY; Pfizer; May 2008.
- ⁸² Vfend [package insert]. New York, NY; Pfizer; May 2008.
- ⁸³ Ancobon [package insert]. Alisa Viejo, CA; Valeant; January 2008.
- ⁸⁴ Available at <http://www.clinicalpharmacology.com>. Accessed January 12, 2010.
- ⁸⁵ Mycelex troche [package insert]. Mountain View, CA; Alza Corporation; February 2003.
- ⁸⁶ Ancobon [package insert]. Alisa Viejo, CA; Valeant; January 2008.
- ⁸⁷ Gris-PEG [package insert]. Farmingdale, NY; Pedinol Pharmcal; January 2007.
- ⁸⁸ Sporanox [package insert]. Raritan, NJ; Pricara; March 2009.
- ⁸⁹ Diflucan [package insert]. New York, NY; Pfizer; March 2008.
- ⁹⁰ Vfend [package insert]. New York, NY; Pfizer; May 2008.
- ⁹¹ Lamisil [package insert]. East Hanover, NJ; Novartis Pharmaceuticals Corporation; March 2004.
- ⁹² Noxafil [package insert]. Kenilworth, NJ; Schering Corp; December 2008.
- ⁹³ Terbinex [package insert]. Charleston, SC; JSJ Pharmaceuticals; June 2009.
- ⁹⁴ Ozturk MA, Gunes T, Koklu E, et al. Oral nystatin prophylaxis to prevent invasive candidiasis in Neonatal Intensive Care Unit. *Mycoses*. 2006; 49(6):484-92.
- ⁹⁵ Kaufman D, Boyle R, Hazen KC, et al. Twice weekly fluconazole prophylaxis for prevention of invasive Candida infection in high-risk infants of <1000 grams birth weight. *J Pediatr*. 2005; 147(2):172-9.
- ⁹⁶ Walsh TJ, Karlsson MO, Driscoll T, et al. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. *Antimicrob Agents Chemother*. 2004; 48(6):2166-72.
- ⁹⁷ Mycelex troche [package insert]. Mountain View, CA; Alza Corporation; February 2003.
- ⁹⁸ Diflucan [package insert]. New York, NY; Pfizer; March 2008.
- ⁹⁹ Ancobon [package insert]. Alisa Viejo, CA; Valeant; January 2008.
- ¹⁰⁰ Gris-PEG [package insert]. Farmingdale, NY; Pedinol Pharmcal; January 2007.
- ¹⁰¹ Available at <http://www.clinicalpharmacology.com>. Accessed January 12, 2010.
- ¹⁰² Sporanox [package insert]. Raritan, NJ; Pricara; March 2009.
- ¹⁰³ Nizoral [package insert]. Titusville, NJ; Janssen; 1998.
- ¹⁰⁴ Available at <http://www.clinicalpharmacology.com>. Accessed January 12, 2010.
- ¹⁰⁵ Noxafil [package insert]. Kenilworth, NJ; Schering Corp; December 2008.
- ¹⁰⁶ Lamisil [package insert]. East Hanover, NJ; Novartis Pharmaceuticals Corporation; March 2004.
- ¹⁰⁷ Lamisil Granules [package insert]. East Hanover, NJ; Novartis Pharmaceuticals Corporation; September 2007.
- ¹⁰⁸ Terbinex [package insert]. Charleston, SC; JSJ Pharmaceuticals; June 2009.
- ¹⁰⁹ Vfend [package insert]. New York, NY; Pfizer; May 2008.
- ¹¹⁰ Mycelex troche [package insert]. Mountain View, CA; Alza Corporation; February 2003.
- ¹¹¹ Diflucan [package insert]. New York, NY; Pfizer; March 2008.
- ¹¹² Gris-PEG [package insert]. Farmingdale, NY; Pedinol Pharmcal; January 2007.
- ¹¹³ Available at <http://www.clinicalpharmacology.com>. Accessed January 12, 2010.
- ¹¹⁴ Nizoral [package insert]. Titusville, NJ; Janssen; 1998.
- ¹¹⁵ Available at <http://www.clinicalpharmacology.com>. Accessed January 12, 2010.
- ¹¹⁶ Lamisil Granules [package insert]. East Hanover, NJ; Novartis Pharmaceuticals Corporation; September 2007.
- ¹¹⁷ Ally R, Schurmann D, Kreisel W, et al. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. *Clin Inf Dis*. 2001; 33:1447-54.
- ¹¹⁸ Elewski BE, Cáceres HW, DeLeon L, et al. Terbinafine hydrochloride oral granules versus oral griseofulvin suspension in children with tinea capitis: results of two randomized, investigator-blinded, multicenter, international, controlled trials. *J Am Acad Dermatol*. 2008; 59(1):41-54.

- ¹¹⁹ Sigurgeirsson B, Billstein S, Rantanen T, et al. L.I.O.N. Study: efficacy and tolerability of continuous terbinafine (Lamisil) compared to intermittent itraconazole in the treatment of toenail onychomycosis. *Lamisil vs. itraconazole in onychomycosis*. *Br J Dermatol*. 1999; 141(suppl 56):5-14.
- ¹²⁰ Sigurgeirsson B, Olafsson JH, Steinsson JB, et al. Long-term effectiveness of treatment with terbinafine vs. itraconazole in onychomycosis: a 5-year blinded prospective follow-up study. *Arch Dermatol*. 2002; 138:353-7.
- ¹²¹ Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. *N Engl J Med*. 2007; 356(4):348-59.
- ¹²² Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. *N Engl J Med*. 2007; 356(4):335-47.
- ¹²³ Vazquez JA, Skiest DJ, Nieto L, et al. A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. *Clin Inf Dis*. 2006; 42(8):1179-86.
- ¹²⁴ Gupta AK, Ryder JE, Johnson AM. Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis. *Br J Dermatol*. 2004; 150(3):537-44.
- ¹²⁵ Gupta AK, Ryder JE, Johnson AM. Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis. *Br J Dermatol*. 2004; 150(3):537-44.
- ¹²⁶ González U, Seaton T, Bergus G, et al. Systemic antifungal therapy for tinea capitis in children. *Cochrane Database Syst Rev*. 2007; (4):CD004685.
- ¹²⁷ Clarkson JE, Worthington HV, Eden OB. Interventions for treating oral candidiasis for patients with cancer receiving treatment. *Cochrane Database Syst Rev*. 2004; 1:CD001972.
- ¹²⁸ Pienaar ED, Young T, Holmes H. Interventions for the prevention and management of oropharyngeal candidiasis associated with HIV infection in adults and children. *Cochrane Database Syst Rev*. 2006; 3:CD003940.
- ¹²⁹ Fleece D, Gaughan JP, Aronoff SC. Griseofulvin versus terbinafine in the treatment of tinea capitis: a meta-analysis of randomized, clinical trials. *Pediatrics*. 2004; 114(5):1312-5.
- ¹³⁰ Gupta AK, Cooper EA, Bowen JE. Meta-analysis: griseofulvin efficacy in the treatment of tinea capitis. *J Drugs Dermatol*. 2008; 7(4):369-72.